Phase II study of the effects of ginger root extract on eicosanoids in colon mucosa in people at normal risk for colorectal cancer

Cancer Prevention Research

Volumn 4, Issue 11, 2011, Pages 1929-1937

  Zick, Suzanna M ^a   Turgeon, D Kim ^a   Vareed, Shaiju K ^d   Ruffin, Mack T ^a   Litzinger, Amie J ^a   Wright, Benjamin D ^a   Alrawi, Sara ^a   Normolle, Daniel P ^a   Djuric, Zora ^a   Brenner, Dean E ^a,b,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

12 HYDROXYOCTADECADIENOIC ACID; 13 HYDROXYOCTADECADIENOIC ACID; 15 HYDROXYICOSATETRAENOIC ACID; 5 HYDROXYOCTADECADIENOIC ACID; ARACHIDONIC ACID; GINGER EXTRACT; ICOSANOID; PLACEBO; PROSTAGLANDIN E2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER RISK; COLON BIOPSY; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FATTY ACID BLOOD LEVEL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NORMAL HUMAN; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SIGMOIDOSCOPY; SINGLE BLIND PROCEDURE; UNSPECIFIED SIDE EFFECT;

ADULT; CHROMATOGRAPHY, LIQUID; COLON; COLORECTAL NEOPLASMS; FEMALE; GINGER; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; MALE; MIDDLE AGED; PLANT EXTRACTS; PLANT ROOTS; PROGNOSIS; RISK FACTORS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; YOUNG ADULT;

EID: 81555226654     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0224     Document Type: Article

References (45)

1. Elwood PC, Gallagher AM, Duthie GG, Mur LA, Morgan G. Aspirin, salicylates, and cancer. Lancet 2009;373:1301-9.
2. Cianchi F, Cortesini C, Fantappie O, Messerini L, Sardi I, Lasagna N, et al. Cyclooxygenase-2 activation mediates the proangiogenic effect of nitric oxide in colorectal cancer. Clin Cancer Res 2004;10:2694-704. (Pubitemid 38509144)
3. Pidgeon GP, Lysaght J, Krishnamoorthy S, Reynolds JV, O'Byrne K, Nie D, et al. Lipoxygenase metabolism: roles in tumor progression and survival. Cancer Metastasis Rev 2007;26:503-24. (Pubitemid 350115127)
4. Ye YN, Wu WK, Shin VY, Bruce IC, Wong BC, Cho CH. Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke. Carcinogenesis 2005;26:827-34. (Pubitemid 41214346)
5. MelstromLG, Bentrem DJ, Salabat MR, Kennedy TJ, Ding XZ, Strouch M, et al. Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors in vitro and in a murine model. Clin Cancer Res 2008;14:6525-30.
6. Soumaoro LT, Iida S, Uetake H, Ishiguro M, Takagi Y, Higuchi T, et al. Expression of 5-lipoxygenase in human colorectal cancer. World J Gastroenterol 2006;12:6355-60. (Pubitemid 44712419)
7. Tong WG, Ding XZ, Talamonti MS, Bell RH, Adrian TE. LTB4 stimulates growth of human pancreatic cancer cells via MAPK and PI-3 kinase pathways. Biochem Biophys Res Commun 2005;335:949-56. (Pubitemid 41188287)
8. Bortuzzo C, Hanif R, Kashfi K, Staiano-Coico L, Shiff SJ, Rigas B. The effect of leukotrienes B and selected HETEs on the proliferation of colon cancer cells. Biochim Biophys Acta 1996;1300:240-6. (Pubitemid 26195822)
9. Nielsen CK, Campbell JI, Ohd JF, Morgelin M, Riesbeck K, Landberg G, et al. A novel localization of the G-protein-coupled CysLT1 receptor in the nucleus of colorectal adenocarcinoma cells. Cancer Res 2005;65:732-42. (Pubitemid 40220345)
10. Bhattacharya S, Mathew G, Jayne D, Pelengaris S, Khan M. 15-Lipoxygenase-1 in colorectal cancer: a review. Tumor Biol 2009;30:185-99.
11. Shureiqi I, Chen D, Day R, Zuo X, Hochman F, Ross W, et al. Profiling lipoxygenase metabolism in specific steps of colorectal tumorigenesis. Cancer Prev Res 2010;3:829.
12. Surh YJ, Lee E, Lee JM. Chemoprotective properties of some pungent ingredients present in red pepperandginger.MutRes 1998;402:259-67. (Pubitemid 28440282)
13. Cavaliere C, Rea P, Lynch M, Blumenthal M. Herbal Supplement sales rise in all channels in 2009: HerbalGram Summer 2010;86:62-6.
14. Koo KL, Ammit AJ, Tran VH, Duke CC, Roufogalis BD. Gingerols and related analogues inhibit arachidonic acid-induced human platelet serotonin release and aggregation. Thrombosis Res 2001;103:387-97. (Pubitemid 32831473)
15. Kiuchi F, Shibuya M, Sankawa U. Inhibitors of prostaglandin biosynthesis from ginger. Chem Pharma Bull (Tokyo) 1982;30:754-7. (Pubitemid 12076282)
16. Mascolo N, Jain R, Jain SC, Capasso F. Ethnopharmacologic investigation of ginger (Zingiber officinale). J Ethnopharmacology 1989;27:129-40. (Pubitemid 20018068)
17. Sharma JN, Srivastava KC, Gan EK. Suppressive effects of eugenol and ginger oil on arthritic rats. Pharmacology 1994;49:314-8. (Pubitemid 24341011)
18. Tjendraputra E, Tran VH, Liu-Brennan D, Roufogalis BD, Duke CC. Effect of ginger constituents and synthetic analogues on cyclooxygenase-2 enzyme in intact cells. Bioorganic Chem 2001;29:156-63. (Pubitemid 34226237)
19. Kiuchi F, Iwakami S, Shibuya M, Hanaoka F, Sankawa U. Inhibition of prostaglandin and leukotriene biosynthesis by gingerols and diarylheptanoids. Chem Pharma Bull (Tokyo) 1992;40:387-91.
20. Nurtjahja-Tjendraputra E, Ammit AJ, Roufogalis BD, Tran VH, Duke CC. Effective anti-platelet and COX-1 enzyme inhibitors from pungent constituents of ginger. Thromb Res 2003;111:259-65. (Pubitemid 38021945)
21. Park KK, Chun KS, Lee JM, Lee SS, Surh YJ. Inhibitory effects of [6]-gingerol, a major pungent principle of ginger, on phorbol ester-induced inflammation, epidermal ornithine decarboxylase activity and skin tumor promotion in ICR mice. Cancer Lett 1998;129:139-44. (Pubitemid 28386594)
22. Suekawa M, Aburada M, Hosoya E. Pharmacological studies on ginger. II. Pressor action of (6)-shogaol in anesthetized rats, or hindquarters, tail and mesenteric vascular beds of rats. J Pharmacobiodyn 1986;9:842-52. (Pubitemid 17203784)
23. Ojewole JA. Analgesic, antiinflammatory and hypoglycaemic effects of ethanol extract of Zingiber officinale (Roscoe) rhizomes (Zingiberaceae) in mice and rats. Phytother Res 2006;20:764-72. (Pubitemid 44408657)
24. Yoshimi N, Wang A, Morishita Y, Tanaka T, Sugie S, Kawai K, et al. Modifying effects of fungal and herb metabolites on azoxymethane-induced intestinal carcinogenesis in rats. Jpn J Cancer Res 1992;83:1273-8. (Pubitemid 23029834)
25. Manju V, Nalini N. Chemopreventive efficacy of ginger, a naturally occurring anticarcinogen during the initiation, post-initiation stages of 1,2 dimethylhydrazine-induced colon cancer. Clinica Chimica Acta 2005;358:60-7. (Pubitemid 40966632)
26. Kim M, Miyamoto S, Yasui Y, Oyama T, Murakami A, Tanaka T. Zerumbone, a tropical ginger sesquiterpene, inhibits colon and lung carcinogenesis in mice. Int J Cancer 2009;124:264-71.
27. Dias MC, Spinardi-Barbisan AL, Rodrigues MA, de Camargo JL, Teran E, Barbisan LF. Lack of chemopreventive effects of ginger on colon carcinogenesis induced by 1,2-dimethylhydrazine in rats. Food Chem Toxicol 2006;44:877-84.
28. Zick SM, Djuric Z, Ruffin MT, Litzinger AJ, Normolle DP, Alrawi S, et al. Pharmacokinetics of 6-gingerol, 8-gingerol, 10-gingerol, and 6-shogaol and conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev 2008;17:1930-6.
29. CTC v2.0 and Common Terminology Criteria for Adverse Events v3.0 (CTCAE) 2007 [cited 2009 June 10]. Available from: http://ctep.cancer.gov/forms/CTCAEv3. pdf.
30. Vareed SK, Kakarala M, Ruffin MT, Crowell JA, Normolle DP, Djuric Z, et al. Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev 2008;17:1411-7.
31. Yang P, Chan D, Felix E, Madden T, Klein RD, Shureiqi I, et al. Determination of endogenous tissue inflammation profiles by LC/MS/MS: COX- and LOX-derived bioactive lipids. Prostaglandins Leukot Essent Fatty Acids 2006;75:385-95. (Pubitemid 44648734)
32. Buczynski MW, Stephens DL, Bowers-Gentry RC, Grkovich A, Deems RA, Dennis EA. TLR-4 and sustained calcium agonists synergistically produce eicosanoids independent of protein synthesis in RAW264.7 cells. J Biol Chem 2007;282:22834-47. (Pubitemid 47267374)
33. Krishnan K, Ruffin MT, Normolle D, Shureiqi I, Burney K, Bailey J, et al. Colonic mucosal prostaglandin E2 and cyclooxygenase expression before and after low aspirin doses in subjects at high risk or at normal risk for colorectal cancer. Cancer Epidemiol Biomarkers Prev 2001;10:447-53. (Pubitemid 32701629)
34. Frommel TO, Dyavanapalli M, Oldham T, Kazi N, Lietz H, Liao Y, et al. Effect of aspirin on prostaglandin E2 and leukotriene B4 production in human colonic mucosa from cancer patients. Clin Cancer Res 1997;3:209-13. (Pubitemid 27107296)
35. Barnes CJ, Hamby-Mason RL, Hardman WE, Cameron IL, Speeg KV, Lee M. Effect of aspirin on prostaglandin E2 formation and transforming growth factor alpha expression in human rectal mucosa from individuals with a history of adenomatous polyps of the colon. Cancer Epidemiol Biomarkers Prev 1999;8:311-5. (Pubitemid 29193902)
36. Ruffin MT, Krishnan K, Rock CL, Normolle D, Vaerten MA, Peters-Golden M, et al. Suppression of human colorectal mucosal prostaglandins: determining the lowest effective aspirin dose. J Natl Cancer Inst 1997;89:1152-60. (Pubitemid 27337930)
37. Venerito M, Treiber G, Wex T, Kuester D, Roessner A, Di Mario F, et al. Effects of low-dose aspirin on gastric erosions, cyclooxygenase expression and mucosal prostaglandin-E2 do not depend on Helicobacter pylori infection. Aliment Pharmacol Ther 2006;23:1225-33. (Pubitemid 43779363)
38. Giardiello FM, Casero RA Jr, Hamilton SR, Hylind LM, Trimbath JD, Geiman DE, et al. Prostanoids, ornithine decarboxylase, and polyamines in primary chemoprevention of familial adenomatous polyposis. Gastroenterology 2004;126:425-31. (Pubitemid 38182299)
39. Thompson PA, Wertheim BC, Zell JA, Chen WP, McLaren CE, LaFleur BJ, et al. Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma. Gastroenterology 2010;139:797-805, 805. e1.
40. Chrubasik S, Pittler MH, Roufogalis BD. Zingiberis rhizoma: a comprehensive review on the ginger effect and efficacy profiles. Phytomedicine 2005;12:684-701. (Pubitemid 41169818)
41. Abrahamson PE, King IB, Ulrich CM, Rudolph RE, Irwin ML, Yasui Y, et al. No effect of exercise on colon mucosal prostaglandin concentrations: a 12-month randomized controlled trial. Cancer Epidemiol Biomarkers Prev 2007;16:2351-6. (Pubitemid 351196367)
42. Guidance for Industry Bioanalytical Method Validation, United States Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research [cited 2011 Feb 21]. Available from: http://www.fda.gov/downloads/Drugs/Guidance-ComplianceRegulatoryInformation/ Guidances/ucm070107.pdf%3E.
43. Poole EM, Hsu L, Xiao L, Kulmacz RJ, Carlson CS, Rabinovitch PS, et al. Genetic variation in prostaglandin E2 synthesis and signaling, prostaglandin dehydrogenase, and the risk of colorectal adenoma. Cancer Epidemiol Biomarkers Prev 2010;19:547-57.
44. Yu Y, Zick S, Li X, Zou P, Wright B, Sun D. Examination of the pharmacokinetics of active ingredients of ginger in humans. AAPS J 2011;13:417-26.
45. Lim S, Cho H, Lee T, Choi C, Min Y, Kim S, et al. Impacts of cytosolic phospholipase A2, 15-prostaglandin dehydrogenase, and cyclooxygenase-2 expressions on tumor progression in colorectal cancer. Yonsei Med J 2010;51:692.